Retinoblastoma is the most common malignant intraocular tumor in children under 5 years old. Survival rates, ocular and visual preservation are major challenges in this disease. This study aims to determine the epidemio-clinical, therapeutic and prognostic profile of patients with retinoblastoma who have been treated in the pediatric hemato-oncology department of the university Hospital Hassan II of Fez. It is a retrospective and descriptive study of all children followed for retinoblastoma at the pediatric hemato-oncology department, over a period of 11 years and 10 months from January 1st, 2012 to October 31, 2023. During this period, we collected 65 cases. The mean age at diagnosis is 25 months and the ratio is 0.9. The mean time to diagnosis is 5 months. Symptoms are dominated by leukocoria (84.2% of cases), followed by exophthalmia (15.8% of cases) and sarbismus (13,2% of cases). The retinoblastoma is unilateral in 70.7% of cases and bilateral in 29,3% of cases. Enucleation was indicated in 97% of cases. The majority of patients were treated by the combination of chemotherapy and surgery (69.2% of cases). Surgery only was indicated in 27,7% of cases and conservative treatment in 26,1% of cases. Radiotherapy was indicated in 9,5% of cases. The overall survival rate at the end of treatment is 75.4% and the five-year survival rate is 60%. The prognosis of retinoblastoma is generally good. In our context, most cases are still diagnosed at advanced stages of the disease, which considerably reduce the overall survival rate and the preservation of the eye and the vision.